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The transition from quiescence to proliferation is a key
regulatory step that can be induced by serum stimulation in
cultured ﬁbroblasts. The transcription factor Myc is directly
induced by serum mitogens and drives a secondary gene
expression program that remains largely unknown. Using
mRNA proﬁling, we identify close to 300 Myc-dependent
serum response (MDSR) genes, which are induced by serum
in a Myc-dependent manner in mouse ﬁbroblasts. Mapping
of genomic Myc-binding sites by ChIP-seq technology
revealed that most MDSR genes were directly targeted by
Myc, but represented a minor fraction (5.5%) of all Myc-
bound promoters (which were 22.4% of all promoters).
Other target loci were either induced by serum in a Myc-
independent manner, were not signiﬁcantly regulated or
were negatively regulated. MDSR gene products were
involved in a variety of processes, including nucleotide
biosynthesis, ribosome biogenesis, DNA replication and
RNA control. Of the 29 MDSR genes targeted by RNA
interference, three showed a requirement for cell-cycle entry
upon serum stimulation and 11 for long-term proliferation
and/or survival. Hence, proper coordination of key
regulatory and biosynthetic pathways following mitogenic
stimulation relies upon the concerted regulation of multiple
Myc-dependent genes.
Oncogene (2012) 31, 1695–1709; doi:10.1038/onc.2011.359;
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Introduction
Quiescent cells can be induced to enter a proliferative
state in vitro through exposure to serum mitogens, a
process associated with widespread changes in gene
expression. Immediate-early serum response genes are
induced directly, in a manner that does not depend upon
prior protein synthesis. Delayed-early genes, on the
other hand, depend upon prior protein synthesis,
suggesting a direct role for immediate-early gene
products in their activation. Consistent with this
concept, immediate-early genes such as c-fos, c-jun
or c-myc encode transcription factors (reviewed by
Winkles, 1998).
The c-myc gene product, Myc, is a transcription
factor that can either activate or repress gene expression.
Activation occurs through dimerization with the partner
protein Max, and binding to the consensus DNA
sequence CACGTG (E-box). Repression occurs through
association of Myc/Max dimers with other transcription
factors such as Miz-1 or NF-Y, and interference with
their function (Izumi et al., 2001; Staller et al., 2001;
Seoane et al., 2002; Mao et al., 2003), although it is
becoming apparent that Myc may also repress tran-
scription through E-boxes (Adhikary and Eilers, 2005).
A number of studies based on chromatin immunopre-
cipitation (ChIP) have shown that Myc associates with a
large (X10–20%) fraction of cellular genes in a variety
of cell types (Fernandez et al., 2003; Li et al., 2003;
Cawley et al., 2004; Zeller et al., 2006; Chen et al., 2008;
Eilers and Eisenman, 2008; Kidder et al., 2008; Kim
et al., 2008). Myc-binding sites are preferentially found
within CpG islands (Fernandez et al., 2003; Zeller et al.,
2006) and within chromatin domains bearing the marks
characteristic of active promoters, such as tri-methyla-
tion of Lys 4 in histone-H3 (H3K4me3) (Guccione et al.,
2006; Kim et al., 2008). While Myc itself may favor the
maintenance of an active chromatin conﬁguration
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www.nature.com/onc(Bouchard et al., 2001; Frank et al., 2001; Knoepﬂer
et al., 2006; Cotterman et al., 2008; Martinato et al.,
2008), this conﬁguration also acts upstream from
Myc, being a pre-requisite for target-site recognition
(Guccione et al., 2006). Consistent with this notion,
RNA PolII was loaded onto Myc-target promoters prior
to—and independently of—Myc binding (Bouchard
et al., 2004; Adhikary and Eilers, 2005), and recent data
suggested that Myc regulates its target genes mainly at
the level of transcriptional elongation in embryonic stem
(ES) cells (Rahl et al., 2010). In summary, Myc binds to
promoters that pre-exist in a transcriptionally active or
poised state, and further modulates their activity.
Several experiments suggested that Myc is required
but not sufﬁcient for the activation of its target genes,
and that other signals must be involved (Frank et al.,
2001; Bouchard et al., 2004). An example is provided by
the target gene Snail: on the one hand, Myc bound to
the Snail promoter and was required for its activation by
transforming growth factor-b signaling in mammary
epithelial cells; on the other hand, binding also occurred
in ﬁbroblasts, but activation of Snail by serum in those
cells did not require Myc (Smith et al., 2009). This
dependence upon context for gene regulation—whether
cell type or environmental context—may also apply to
overexpressed Myc in cancer cells, as suggested for
example by the comparison of gene expression proﬁles
in Myc-induced prostate carcinomas in the mouse and a
subset of human prostate carcinomas (Ellwood-Yen
et al., 2003). These observations might allow under-
standing why, in spite of multiple gene expression
proﬁles described over the years (see www.myccancer
gene.org/), Myc activity had not clearly been associated
with a universal mRNA signature. Uncovering common
denominators in Myc-driven transcription, however,
may also depend upon the analytical tools used. For
example, linkage and gene-set analysis allowed the
identiﬁcation of Myc as a causal factor in two gene
signatures activated in a subset of carcinomas: a serum
response/wound-healing program initially discovered in
ﬁbroblasts (Chang et al., 2004; Adler et al., 2006), as
well as an ‘embryonic stem cell (ESC)-like’ expression
proﬁle (Wong et al., 2008). A recent re-analysis
distinguished the latter as a Myc-driven program
common to ES and cancer cells, but distinct from the
core pluripotency program in ES cells (Kim et al., 2010).
The data described so far did not address whether Myc-
associated signatures in cancer cells were related to its
action in normal cells, in particular in the serum
response.
We showed previously that Myc binding to several
target promoters was required for their activation by
serum (Frank et al., 2001). Here, we proﬁled the full
contribution of Myc to the serum response in immorta-
lized mouse ﬁbroblasts. The c-myc gene was deleted in
quiescent 3T9 ﬁbroblasts homozygous for a conditional
knockout allele (Trumpp et al., 2001), followed by
serum stimulation and mRNA proﬁling. In parallel, we
mapped Myc–DNA interactions at the genome-wide
level in serum-treated cells. Altogether, these data
provide a comprehensive picture of the core transcrip-
tional program regulated by Myc in response to serum
mitogens.
Results
Part of the transcriptional program activated by serum in
ﬁbroblasts is Myc-dependent
To study the role of Myc in the serum response, we took
advantage of immortalized 3T9 ﬁbroblasts derived from
homozygous c-myc
f/f mice bearing loxP sites in the ﬁrst
intron and in the 30-untranslated region of the c-myc
gene (Trumpp et al., 2001). These cells were transduced
with a retroviral vector expressing a chimeric CreER
recombinase (hereafter myc
f/f;CreER cells), allowing
conditional deletion of c-myc upon treatment with
4-hydroxytamoxifen (OHT). To achieve quiescence,
near-conﬂuent cultures were serum-starved for 2 days,
either with or without OHT: in this manner, the c-myc
gene was deleted at the time at which its expression is
normally suppressed, interfering minimally with cellular
ﬁtness. Cells were then re-seeded in medium containing
10% fetal calf serum and harvested for analysis at the
indicated time points (Figure 1a). Serum-induced
accumulation of the c-myc mRNA in OHT-treated cells
was reduced to 15–20% of that seen in control cells
(Figure 1b) (Smith et al., 2009), mirroring the residual
levels of the c-myc gene in the treated cells (Figure 1c).
Thus, the c-myc
f/f allele was efﬁciently deleted in X80%
of the cells upon CreER activation, with residual
mRNA levels originating from a minority of undeleted
cells. c-myc deletion prevented re-entry in S-phase
following serum stimulation (Figure 1d) (Trumpp
et al., 2001) and blunted the response of the Myc-target
genes Ncl and Ppat (Smith et al., 2009), as observed
previously in Rat1 cells (Frank et al., 2001). We thus
used oligonucleotide microarrays to proﬁle mRNA
expression in control and OHT-treated myc
f/f;CreER cells
at 0, 4 and 8h following serum stimulation. Based on a
series of criteria outlined under Materials and methods,
we identiﬁed three groups of genes that followed distinct
regulatory patterns (Supplementary Table S1): a Myc-
dependent serum response (MDSR, 298 genes), a Myc-
independent serum response (MISR, 289 genes) or no
response to serum (NRS, 631 genes). The difference
among the three regulatory groups was most evident
when visualized by hierarchical clustering (Eisen et al.,
1998), with the MDSR group clearly composed of
mRNAs induced in control, but not—or less—in Myc-
deleted cells (Figure 2). The induction of each MDSR
mRNA and its reduction without Myc are also plotted
in Supplementary Figure S1A. As expected, this group
included c-myc itself, Ncl, Ppat and Hspd1 (Frank et al.,
2001), as well as 72 genes previously identiﬁed as being
Myc-regulated (www.myccancergene.org/) (Zeller et al.,
2003) (Supplementary Table S1). Other genes that
responded to serum in a Myc-dependent manner in
Rat1 cells (Frank et al., 2001) were lost from our list,
either because of the stringency of our selection criteria,
such as Cad, Nme2 (Nm23-H2) and Hspe1, or because
Genomic and transcriptional proﬁling of the Myc-dependent serum response
D Perna et al
1696
Oncogenethey were not Myc-dependent in our experimental
system, like Odc1.
We also addressed the behavior in our experimental
system of 230 genes reported previously to be upregu-
lated upon Myc overexpression in Rat1 cells (list ‘Up in
rat’; Supplementary Table S2), identiﬁed mainly in
proﬁling studies compiled in the Myc database
(www.myccancergene.org) (Zeller et al., 2003). As
shown in Supplementary Figure S2A and Supplemen-
tary Table S2, the majority of these genes responded
positively to serum in our cells, but only few showed
overlap with MDSR genes (37/230 or 16%). Limiting
our analysis to the subset of genes identiﬁed in multiple
studies improved the overlap with MDSR genes to up to
32% (Supplementary Table S3). Altogether, our data
indicate that those genes that depend upon endogenous
Myc (that is, our MDSR list) show only a partial
overlap with genes that are induced upon ectopic Myc
activation. A screen for Myc-inducible genes in mouse
ﬁbroblasts (our unpublished data) yielded the same
conclusion.
To validate our microarray expression data, we
repeated three independent experiments and measured
mRNA levels for 45 MDSR genes by quantitative
reverse transcription (RT)–PCR at 0, 4, 8 and 12h
following serum stimulation. Figure 3a reports fold-
activation for each mRNA at its peak time: 43 mRNAs
(93.5%) showed a X1.5  serum response in control
cells, with a signiﬁcant reduction in Myc-deleted cells
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Figure 1 Conditional deletion of the c-myc gene in quiescent cells
impairs cell-cycle re-entry. (a) A schematic representation of the
experimental approach. Near-conﬂuent cultures of myc
f/f;CreER
ﬁbroblasts were serum-starved for 48h with or without OHT to
induce c-myc deletion. Following stimulation with 10% fetal calf
serum, RNA was isolated at the indicated time points for proﬁling
(Figure 2). (b) c-myc mRNA levels were measured in myc
f/f;CreER
cells, either without (control) or with OHT to induce c-myc deletion
(D c-myc), followed by serum stimulation, as indicated. The data
were normalized to 36B4 mRNA. The average±s.d. of three
independent experiments is shown. (c) Relative amount of c-myc
genomic DNA measured by quantitative RT–PCR in myc
f/f;CreER
cells left untreated (black bars) or treated with OHT (gray bars).
Values were normalized to a PCR amplicon in the Nucleolin locus,
and represent the average±s.d. from three independent experi-
ments. (d) Cumulative percentages of cells traversing S-phase over
24h of fetal calf serum stimulation in cultures treated as above.
BrdU was added to the culture medium at time 0, and
incorporation was assayed by ﬂow cytometry.
FCS (h): 0 4 8 0 4 8 0 4 8 0 4 8 0 4 8 0 4 8
- OHT + OHT - OHT + OHT - OHT + OHT
MDSR MISR NRS
Induced repressed
10 7.5 5 2.5 1 0.75 0.5 0.25 0.1
Figure 2 Identiﬁcation of regulatory patterns following Myc
deletion and serum stimulation. The heatmaps show the different
classes of gene identiﬁed by their expression patterns: MDSR,
MISR and NRS. The genes in each group were clustered
hierarchically on the basis of their microarray-based expression
proﬁles. Changes in mRNA levels were expressed as fold-induction
relative to time 0 in each culture, and color-coded as indicated.
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Oncogene(Pp0.01). Only two mRNAs failed this test, lacking
either induction or signiﬁcant Myc dependence
(asterisks in Figure 3a). RT–PCR validation also con-
ﬁrmed that 10 genes in the MISR group were induced by
serum in a Myc-independent manner, and that 9 out of
10 NRS genes showed no response, with only one
(STAT3) showing a moderate induction (Supplementary
Figure S3). Thus, RT–PCR conﬁrmed the reliability of
the regulatory patterns identiﬁed in our proﬁling
experiments. We conclude that MDSR genes constitute
the core transcriptional response built up by Myc during
the G0-G1/S-phase progression.
Analysis of Myc-repressed gene during serum stimulation
Myc has also been shown to repress transcription
(Adhikary and Eilers, 2005). Upon serum stimulation,
0
15
30
45
60
75
90
105
120
135
150
O
C
R
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
%
 
 
I
n
p
u
t
 
no serum 
serum 
0
2
4
6
8
10
12
14
16
18
20 a
b
F
o
l
d
-
i
n
d
u
c
t
i
o
n
-OHT c-myc intact
+OHT c-myc deleted
56.6
S
e
r
p
i
n
b
1
a
M
c
m
5
2
6
1
0
3
0
1
F
0
2
R
i
k
P
a
i
p
2
b
S
o
x
1
1
P
r
p
s
1
M
c
m
6
R
b
b
p
4
U
m
p
s
2
4
1
0
0
1
5
N
1
7
R
i
k
9
5
3
0
0
5
8
B
0
2
R
i
k
P
c
g
f
6
S
s
b
G
a
r
t
N
u
t
f
2
A
h
c
y
S
f
r
s
7
F
a
m
6
0
a
C
d
k
4
S
m
y
d
2
E
x
o
s
c
2
T
h
o
p
1
D
1
9
B
w
g
1
3
5
7
e
C
c
t
7
3
1
1
0
0
8
2
I
1
7
R
i
k
C
s
n
k
2
a
1
H
s
p
d
1
G
n
l
2
M
t
h
f
d
1
T
a
f
1
d
S
e
r
b
p
1
I
m
p
d
h
2
B
r
p
1
6
A
p
e
x
1
K
a
t
2
a
R
r
p
1
b
C
1
q
b
p
A
t
a
d
3
a
C
s
d
a
P
r
m
t
3
B
x
d
c
1
N
c
l
R
p
l
1
4
G
p
a
t
c
h
4
M
y
b
b
p
1
a
S
e
r
p
i
n
b
1
a
M
c
m
5
2
6
1
0
3
0
1
F
0
2
R
i
k
P
a
i
p
2
b
S
o
x
1
1
P
r
p
s
1
M
c
m
6
R
b
b
p
4
U
m
p
s
2
4
1
0
0
1
5
N
1
7
R
i
k
9
5
3
0
0
5
8
B
0
2
R
i
k
P
c
g
f
6
S
s
b
G
a
r
t
N
u
t
f
2
A
h
c
y
S
f
r
s
7
F
a
m
6
0
a
C
d
k
4
S
m
y
d
2
E
x
o
s
c
2
T
h
o
p
1
D
1
9
B
w
g
1
3
5
7
e
C
c
t
7
3
1
1
0
0
8
2
I
1
7
R
i
k
C
s
n
k
2
a
1
H
s
p
d
1
G
n
l
2
M
t
h
f
d
1
T
a
f
1
d
S
e
r
b
p
1
I
m
p
d
h
2
B
r
p
1
6
A
p
e
x
1
K
a
t
2
a
R
r
p
1
b
C
1
q
b
p
A
t
a
d
3
a
C
s
d
a
P
r
m
t
3
B
x
d
c
1
N
c
l
R
p
l
1
4
G
p
a
t
c
h
4
M
y
b
b
p
1
a
*
*
*
mRNA induction by serum (qRT-PCR)
DNA binding (qChIP)  
DNA binding (ChIP-seq)  
Figure 3 The MDSR genes are enriched for direct Myc targets. (a) Quantitative RT–PCR validation of 45 MDSR genes. The
expression of each mRNA at the time point of maximal activation by serum is shown in Myc-expressing cells ( OHT, blue bars)
alongside Myc-deleted cells (þOHT, red bars). The data are the average±s.d. of three independent experiments. The asterisks mark
the three genes that were not validated according to our criteria (see text). (b) Binding of Myc to the corresponding promoters
(TSS±1kb), as assayed by qChIP (top) and ChIP-seq (bottom). Cells were either starved for 2 days (blue bars) or stimulated with
serum for 8h (red bars) before harvesting.
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Oncogenethe mRNAs of Myc-repressed genes would be expected
to show either of two patterns in Myc-deleted cells
relative to controls: (i) loss of repression by serum (that
is, Myc-dependent repression) or (ii) super-activation in
the absence of Myc. In our microarray proﬁles, 130
genes apparently followed the ﬁrst of these criteria
(Supplementary Table S1 and Supplementary Figure
S2B): however, when tested by quantitative RT–PCR,
only 7/20 (35%) of the corresponding mRNAs con-
ﬁrmed this pattern, whereas nine (45%) were validated
as repressed by serum but not as Myc-dependent
(Supplementary Figure S4A). We also identiﬁed a group
of 65 genes, which were super-induced by serum in the
absence of Myc (Supplementary Table S1 and Supple-
mentary Figure S2C). RT–PCR analysis validated the
antagonizing role of Myc for 4/13 (30%) of these genes
(Mmp9, Fdps, Abr and Cdkn1a, encoding p21
Cip1)
(Supplementary Figure S5). In both of the above
groups, several other genes tested by RT–PCR showed
an apparent Myc dependence, which however remained
below statistical signiﬁcance (Supplementary Figures
S4A and S5).
We further compiled a list of 41 genes including
(i) previously reported Myc-repressed genes, (ii) genes
listed as serum-repressed and Myc-dependent in rat
ﬁbroblasts (Watson et al., 2002), and (iii) genes listed in
the Myc database as repressed and Myc-bound in any
species (Supplementary Table S2). However, these genes
showed very disparate behaviors in our microarray
proﬁles in terms of serum activation, repression or Myc-
dependence (Supplementary Figure S2D). Only eight
(20%) of these genes (Acp5, Gadd45, Rara, Tmsb4x, Vhl,
Zfp36l1, Cdkn1a and Cdkn2b, encoding p15
INK4b)
showed a pattern consistent with their negative regula-
tion by Myc (given our stringency criteria, only Cdkn1a
had been included in the above ‘super-induced’ group).
RT–PCR analysis of Cdkn2b and Gadd45 validated their
negative regulation by Myc (Supplementary Figure
S4B); Gadd45a, in particular, is repressed by Myc
overexpression (Marhin et al., 1997; Amundson et al.,
1998; Tao and Umek, 1999) and, consistent with our
data, was previously reported to be repressed by serum
in a Myc-dependent manner (Bush et al., 1998).
Altogether, and as concluded above for Myc-activated
genes, only a fraction of the genes that are repressed by
overexpressed Myc also show evidence for repression by
endogenous Myc upon serum stimulation.
Our data are consistent with the concept that negative
gene regulation by Myc represents an important facet of
its activity in the mitogenic response. However, because
Myc-dependent repression in our microarray proﬁles
was validated to a lesser extent than Myc-dependent
activation, we will concentrate here on the latter.
MDSR genes are direct Myc targets, but are a minor
fraction of all the genes bound by Myc in the genome
In parallel with gene expression, we used ChIP-seq to
proﬁle Myc binding in the genome of c-myc
f/f
3T9 ﬁbroblasts. Cells were ﬁxed for ChIP analysis
either before (0h) or after serum stimulation (8h),
and chromatin was immunoprecipitated with a
Myc-speciﬁc antibody. The recovered DNA was con-
trolled by PCR ampliﬁcation of known Myc-binding
sites (data not shown), followed by ultra-high-throughput
sequencing. In order to identify and quantify Myc-binding
sites along the genome, we applied the following criteria.
First, an overlap count value was determined for every
base in the genome, indicating the number of sequence
tags overlapping that position. Second, overlap count was
normalized to sequencing depth in either library (0 and
8h), yielding the ‘overlap count-resampled’ (OCR) value,
which represents a measure of binding intensity: to
eliminate sequencing artifacts, we only retained sites
showing over ﬁvefold enrichment in OCR relative to
input chromatin (Chen et al., 2008). The ChIP-seq proﬁles
at two representative Myc-target loci are shown alongside
their validation by quantitative ChIP (qChIP) with
successive PCR amplicons (Figure 4a). qChIP validation
of 76 peaks (45 at MDSR and 31 at randomly selected
loci) showed a good correlation with relative ChIP-seq
values, either before or after serum stimulation (Figure 3b
and Supplementary Figure S6). As expected based on the
induction of Myc by serum, Myc binding intensity was
generally higher in serum-stimulated cells (Figure 3b and
Supplementary Figure S1B).
To facilitate the comparison of the two data sets,
OCR values were further subjected to robust multi-array
average (RMA) normalization (Irizarry et al., 2003).
Whereas the OCR is a measure of Myc binding intensity
at a given site, the RMA-normalized value (henceforth
OCR-RMA) is proportional to the relative afﬁnity of
Myc for the corresponding site. Indeed, whereas OCR
values were much higher in serum-stimulated relative
to starved cells, reﬂecting differences in Myc levels
(Supplementary Figure S1B), OCR-RMA values were
generally closer between the two conditions (Supple-
mentary Figure S1C). Interestingly, however, a subset of
the sites targeted in serum-stimulated cells showed no
signiﬁcant binding in quiescent cells (Figure 3b and
Supplementary Figure S1C), suggesting that a fraction
of the Myc-binding sites are themselves induced by
serum. The nature of this phenomenon remains to be
addressed, but may conceivably be linked to changes in
local chromatin conﬁguration, which can modulate
DNA recognition and Myc binding (Guccione et al.,
2006).
Peaks with the lowest levels of enrichment in ChIP-
seq may reﬂect non-sequence-speciﬁc interactions of
Myc with chromatin, rather than binding to bona ﬁde
target sites. To discriminate among those modes of
binding, we reasoned that peaks occurring only in
quiescent cells and with the lowest intensities where the
most likely to be nonspeciﬁc. Of all the peaks in the no-
serum data set, 37% were not found in serum-stimulated
cells: applying a cut-off at an OCR-RMA of 15 reduced
this proportion to 16.3%. In addition, binding sites
below that value in serum-stimulated cells were mini-
mally enriched for the consensus E-box relative to
unbound sites (see below; Table 1). We thus applied
OCR-RMA X15 as threshold of conﬁdence for Myc
binding in both data sets. Following this criterion, we
identiﬁed 4749 and 8632 peaks in serum-starved and
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Figure 4 Distribution of Myc-binding peaks in the genome. (a) Examples of ChIP-seq proﬁles in serum-starved and stimulated cells
are shown for two Myc-target loci, Serbp1 and Smyd2, aligned with CpG islands, E-boxes, the PCR amplicons used for validation and
the corresponding qChIP proﬁles (bottom graphs). The qChIP data represent the average±s.d. from three independent experiments.
(b) Relative frequency of peaks in the genomic window ±2kb from all annotated TSSs, represented for cells without (black line) or
with serum (red line). The vertical dotted line represents the mode of the distributions. (c) Box plots reporting the distribution of Myc-
binding intensities (OCR-RMA) at peaks within ±1kb from the TSS, shown separately for genes within each of the indicated
regulatory patterns. Only genes bound above threshold were considered for each group (see text).
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As 82.2% of the peaks in the no-serum samples
overlapped with those in serum-stimulated cells, we will
concentrate mainly on the latter.
To determine the distribution of Myc relative to
genes, we aligned our ChIP-seq peaks with the
annotated RefSeq data set (Supplementary Table S4).
In both data sets, Myc-binding sites were clearly
concentrated around transcription start sites (TSSs)
and decreased with distance from the TSS (Figure 4b
and Supplementary Figure S7A). In serum-stimulated
cells, 47.1% of the peaks occurred between  1000 and
þ1000bp relative to the TSS, with maximal occurrence
just before the TSS (Figure 4b, 535 peaks between 0 and
 50). Based on this observation, we will deﬁne Myc-
bound promoters as those with a peak within ±1kb
from the TSS. Another 22.4% of the peaks occurred
further downstream inside genes (henceforth labeled
‘intragenic-only’, that is, from 41000bp from the TSS
to the 30 end) and 30.4% occurred further upstream or
further downstream outside genes (‘intergenic’; Supple-
mentary Table S4; see Materials and methods). As
expected, a majority (75.5%) of the TSS-proximal sites
occurred within a CpG island. A total of 6.7% and
13.2% of the intragenic-only and intergenic sites,
respectively, were also in CpG islands (Supplementary
Table S4, statistics) and hence were most likely proximal
to either an alternative TSS for the same gene, or the un-
annotated TSS of an alternative locus. Indeed, 85%
(2234/2628) of the intergenic sites occurred within
±1kb from a CAGE tag (Supplementary Figure S7B),
indicating their proximity to the 50 end of an RNA
transcript (Kawaji et al., 2009). Altogether, about half
of all Myc-binding sites are proximal (within±1kb) to a
TSS, with most of these sites occurring within CpG
islands.
We then asked which proportion of the MDSR genes
were direct targets of Myc. Remarkably, 234 out of
298 MDSR genes (78.5%) were bound by Myc within
±1000bp from the TSS at levels above the threshold
of OCR-RMA X15 (Supplementary Tables S5 and S6).
One additional MDSR gene showed a Myc binding
peak just outside the ±1-kb boundary and was thus
reassigned as direct Myc-target (Tardbp, þ1061bp).
Forty-ﬁve genes showed a peak within the same window
but below the threshold, and 19 scored as devoid of any
peak. Of the latter, 13 did not score as nearer neighbors
of any peak in our ChIP-seq data set (and were thus
absent from Supplementary Table S4), whereas six
were nominally associated with a peak, but at much
larger distances (between  11 and  73kb, or þ20 and
þ250kb). The corresponding peaks were located either
within a CpG island or near a more recently identiﬁed
TSS (data not shown), indicating that they belonged to
other loci, rather than to distal enhancers of these
MDSR genes. We conclude that MDSR genes without a
TSS-associated peak (19/298 or 6.4%) were indirectly
regulated by Myc. Altogether Myc directly controls the
activity of most MDSR genes, and does so through
proximal promoter elements.
In our whole ChIP-seq data set, 4284 of 19157
annotated promoters (22.4%) scored as Myc-bound in
serum-stimulated ﬁbroblasts (with OCR-RMA X15;
Supplementary Table S6). MDSR loci represented a
minor fraction of all Myc-bound promoters (234/4284
or 5.5%) but, most remarkably, also showed signiﬁ-
cantly higher Myc-binding signals (Figure 4c). Myc also
associated with 47.8% (138/289) and 44.4% (280/631) of
the MISR and NRS promoters, respectively (Supple-
mentary Table S6), but unlike MDSR promoters these
did not show elevated signals (Figure 4c). Most
importantly, however, efﬁcient binding by Myc was
not a unique characteristic of MDSR promoters, as
shown by the existence of 650 ‘high-afﬁnity non-MDSR’
peaks (Figure 4c). The latter were operationally deﬁned
by elevated Myc binding (OCR-RMA X35.5 or the top
15% of all peaks in serum-stimulated cells) and their
association with MISR promoters (23 peaks), NRS
promoters (60 peaks) or promoters not listed in either
category (567 peaks; Supplementary Table S4): account-
ing for bi-directional promoters, these sites were
associated with a total of 718 genes (listed in Supple-
mentary Table S6). Hence Myc-dependent regulation
was not determined solely by Myc-binding afﬁnity.
ChIP-seq reveals the hierarchical determinants
of Myc–DNA interactions in vivo
CpG islands are preferred domains for deposition of the
histone methylation mark H3K4me3 (Bernstein et al.,
2006; Guenther et al., 2007) owing to their direct
Table 1 For each of the ﬁve gene groups (i. to iv.), the table shows the percentage of TSSs located within a CpG island and the percentage of
promoters containing a CACGTG motif within ±1kb of the TSS
Group Promoters Total CpG islands CACGTG
% P-value % P-value
i. MDSR, Myc-bound 234 86.8 0 62.4 0
ii. High-afﬁnity non-MDSR promoters (RMAX35,5) 718 87.0 0 59.1 0
iii. Low-afﬁnity non-MDSR promoters (15oRMAo35,5) 3355 83.5 0 41.3 0
iv. Myc peak below threshold (OCR-RMA p15) 4803 76.4 0 29.0 0.852
v. No peak 10672 23.4 1 22.3 1
Abbreviation: TSS, transcription start site.
The enrichment P-value for CpG islands was calculated by using binomial distribution assuming a frequency of TSS located in a CpG island of
0.473 (9731/20570). The enrichment P-value for the CACGTG motif was calculated by using binomial distribution assuming a frequency of
CACGTG motif within 1kb of a TSS of 0.283325 (5828/20570).
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transferase complex (Thomson et al., 2010). Consistent
with this association, Myc-binding sites are preferen-
tially located within CpG islands (Fernandez et al.,
2003; Zeller et al., 2006) and are enriched for H3K4me3
(Guccione et al., 2006; Kim et al., 2008). We previously
proposed that recognition of this active chromatin
environment constitutes the limiting step for target
recognition in vivo (Guccione et al., 2006). An untested
corollary of this mechanism was that, even in the
absence of a high-afﬁnity binding site, Myc should be
detectable at basal levels on promoters with a permissive
chromatin environment. Taking CpG islands as surro-
gate markers for active chromatin allowed us to validate
this prediction in our data set: ﬁrst, relative to
promoters devoid of any Myc-binding peak (Group-v.;
Table 1), those with a Myc peak below threshold (OCR-
RMA o15; Group-iv.) were already enriched for CpG
islands, although not for the E-box consensus. Second,
the E-box was enriched at intermediate levels in the
promoters bound by Myc with low-to-medium afﬁnity
(OCR-RMA 15–35.5: Group-iii.) and at higher levels in
both the MDSR and high-afﬁnity non-MDSR groups
(i./ii.). Another corollary was that, if Myc associates
with transcriptionally active or poised promoters, loci
with increasing Myc-binding efﬁciencies (as assessed
following serum stimulation) should show correspond-
ingly higher median mRNA levels prior to Myc
activation (that is, before serum stimulation): analysis
of our data conﬁrmed this trend (Supplementary Figure
S8). Altogether, these observations are fully consistent
with the concept that Myc initially recognizes CpG
island-associated chromatin in a non-sequence-speciﬁc
manner, most likely involving interactions with other
chromatin-associated proteins, followed by sequence
speciﬁc DNA binding.
Effect of core E-box variants and ﬂanking nucleotides on
DNA binding in vivo
We exploited our ChIP-seq data set to further address
the sequence speciﬁcity of Myc–DNA interactions
in vivo. First, we addressed the enrichment of all
possible hexamers in promoters bound by Myc with
low-to-intermediate (OCR-RMA 15–35.5) or high
afﬁnity (OCR-RMA 435.5) (Supplementary Table
S7A). The consensus CACGTG (henceforth numbered
#1) was the most signiﬁcantly enriched motif in both
groups. Four core variants, CACGCG, CATGCG,
CACGAG and CATGTG (henceforth #2–5), were also
enriched signiﬁcantly, albeit at lower levels, most of the
high-afﬁnity binding by Myc being associated with the
presence of the canonical core #1 (Figure 5). Remark-
ably, the same variant motifs were identiﬁed previously
as Myc/Max-binding sites based on oligonucleotide
selection in vitro (Blackwell et al., 1993) and sequencing
of 27 sites recovered by ChIP (Grandori et al., 1996).
Other signiﬁcantly enriched hexamers (Supplementary
Table S7A) contained partial matches to the above core
motifs (in particular half-sites), and in a few cases the
Ets motif (see below), but none of the 13 remaining
CANNTG E-box variants were enriched.
We then addressed the effect of the nucleotides
ﬂanking either side of the core motifs #1–5: For this
analysis, each one of the positions at ±1, ±2o r±3
was considered independently from the others, thus
reﬂecting the tendency of each core to enrich for a given
base at each of those positions (Supplementary Table
S7B–D; summarized in Table 2). Core #1 was the most
tolerant at the proximal positions (±1), with a strong
preference for C or G, and to a lower extent for A on the
50 side (and their complement on the 30), in various
combinations. Sites with T before or A after the core
were not enriched, consistent with experiments using
in vitro oligonucleotide selection with Myc/Max dimers
(Solomon et al., 1993) or yeast as a heterologous in vivo
system (Fisher et al., 1993). Although with different
levels of signiﬁcance, Myc binding to core #1 enriched
for any combination of bases at positions ±2 and ±3,
allowing a simple consensus with this canonical E-box
(Table 2). The core variants #2–5 allowed fewer
combinations of ﬂanking nucleotides at either position
(Table 2 and Supplementary Table S7): at position ±1
for example, the preferred combination was C-core-G
for core #4 and G-core-C/T for core #3. In two instances
(position ±2 with core #2 and position ±3w i t hc o r e
#5), the base on one side inﬂuenced that on the other,
resulting in different combinations of preferred bases
(Table 2). Most remarkably, several of the motifs that
were not enriched among high-afﬁnity targets were
still enriched among the low-afﬁnity targets (for
example, TCACGTGG or GGACGCGC; Supplemen-
tary Table S7B). Altogether, our data indicate that
variations in the core allow efﬁcient binding, provided
the presence of a restricted set of ﬂanking bases. This
accounts for the fact that the canonical CACGTG
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Figure 5 Relative Myc-binding afﬁnity for the different E-box
core motifs. The DNA sequence in the window ±250bp from each
Myc-binding peak in serum-treated cells was analyzed. Peaks with
OCR-RMA o15 were not included. Only sequences containing
exactly one type of core E-box variant (#1–5) were considered. The
distribution of OCR-RMA values associated with each peak is
shown as box plots, along with t-test P-values relative to core #1.
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sites in vivo (Table 1).
Effect of DNA-binding sites on gene regulation
We then addressed whether the Myc-dependent serum
response—as opposed to DNA binding per se—might be
determined by distinct sequence elements in target
promoters. The Myc-bound MDSR promoters and the
high-afﬁnity non-MDSR promoters showed very similar
percentages of either the consensus E-box (CACGTG) or
CpG islands (groups i. and ii.; Table 1). Both of these
features were signiﬁcantly enriched relative to the
promoters with no Myc-binding peak in ChIP-seq
(Group-v.), fully consistent with their roles in determining
Myc–DNA interactions in vivo (see below). Most
importantly here, our data also demonstrate that these
features are insufﬁcient to determine Myc-dependent
regulation. In addition, the binding sites (deﬁned as
Position Weight Matrices) that were enriched among
the Myc-bound MDSR promoters were also present in
the high-afﬁnity non-MDSR group (Supplementary Table
S8, see legend). Thus, at this level of resolution the
differential regulation of MDSR genes could be attributed
neither to preferential DNA binding by Myc, nor to the
presence of secondary transcription factor-binding sites.
It is noteworthy that other motifs, in particular ETS
consensus sites, were also enriched at Myc-binding sites
(Supplementary Tables S7A and S8), suggesting that
Myc may positively interact with other factor(s) for
DNA binding. The molecular basis for this association
remains to be addressed.
Finally, the binding of Myc to negatively regulated
genes deserves a note here: the Myc-bound fraction for
these genes is lower than in the other groups, being 23%
(15/65) and 22% (29/130) for the super-induced and
serum repressed Myc-dependent promoters, respectively
(Supplementary Table S6). Motif analysis for the genes
super-induced without Myc failed to ﬁnd a signiﬁcant
enrichment for Myc-binding sites, whereas it revealed
two motifs in common with the list of the high-afﬁnity
non-MDSR group (Klf7 and Sp4) and three additional
motifs, NF-Y, TBP and SRF (Supplementary Table S8).
These observations point to possible roles of the latter
factors in negative gene regulation by Myc—consistent
with previous observations for NF-Y (Izumi et al.,
2001)—but given the lower rate of RT–PCR validation
for the negatively regulated groups in our experiments
(see above), their relevance remains to formally be
addressed.
MDSR genes are enriched for speciﬁc regulatory
pathways
Gene Ontology (GO) analysis with the NIH-DAVID suite
(http://david.abcc.ncifcrf.gov/home.jsp) (Dennis et al.,
2003) and with Ingenuity Pathway Analysis 8.6 (http://
www.ingenuity.com) consistently indicated that the
MDSR group was enriched for genes involved in
metabolic processes, nucleotide/DNA/RNA metabolism,
ribosome biogenesis and translation, RNA/rRNA/tRNA
processing, gene expression, DNA replication and cell-
cycle control (Supplementary Table S9). In line with
previous observations, MDSR genes included key en-
zymes in purine and pyrimidine biosynthetic pathways,
including Prps1, Ppat, Gart, Pfas, Impdh2, Umps and
Rrm2 (Liu et al., 2008), as well as genes involved in one-
carbon pool and methionine metabolism (Nikiforov et al.,
2002). Other MDSR genes encoded proteins directly
involved in DNA replication, including four subunits of
the Mcm helicase complex (Blow and Dutta, 2005; Blow
and Tanaka, 2005) as well as Dbf4, the regulatory subunit
of the Cdc7 kinase, a regulator of Mcm activity (Masai
et al., 2005). Thus, in this experimental setting, Myc
regulated a substantial group of genes involved in cell-
cycle progression, cell growth, RNA, DNA and nucleo-
tide metabolism, and DNA replication.
MDSR gene products also included three subunits
of the exosome complex, which has a central role in
mRNA decay/surveillance and in the processing of
rRNA, snoRNA and snRNA molecules (Vanacova and
Steﬂ, 2007; Schmid and Jensen, 2008). The mammalian
exosome has a ring-shaped part, composed of six
different polypeptides, and a top cap composed of three
proteins, required for the stability and function of the
whole structure (Liu et al., 2006; Shen and Kiledjian,
2006). Exosc8 (or Rrp43) in the ring-shaped moiety, and
Exosc2 (or Rrp4) and Exosc3 (or Rrp40) in the cap,
were encoded by MDSR genes suggesting that Myc
activity may be limiting for exosome function.
Table 2 Core E-box motifs with ﬂanking nucleotides at each of the indicated positions were analyzed for enrichment in high-afﬁnity peaks (OCR-
RMA X35.5) as described in Supplementary Table S7
Core: CACGTG (#1) CACGCG (#2) CATGCG (#3) CACGAG (#4) CATGTG (#5)
Positions ±1 VCACGTGBS CACGCGGG CATGCGYC CACGAGGC CATGTGC
Positions ±2 N-CACGTG-N
C-CACGCG-M
A-CACGCG-C
T-CACGCG-T
C-CATGCG-AA -CACGAG-CW -CATGTG-T
Positions ±3 N--CACGTG--NA --CACGCG--CG --CATGCG--RG --CACGAG--C T--CATGTG--C
G--CATGTG--T
consensus NNVCACGTGBNN
ACSCACGCGGMC
AASCACGCGGCC
ATSCACGCGGTC
GCGCATGCGYAR GACCACGAGGCC TWCCATGTGCTC
GWCCATGTGCTT
Abbreviations: OCR, overlap count-resampled; RMA, robust multi-array average.
Motifs with an enrichment P-value p0.001 were considered as signiﬁcantly enriched and are shown using IUPAC codes.
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Myc-associated proﬁles
To address whether the gene lists identiﬁed here were
signiﬁcantly represented in previous data sets, we
selected 85 relevant publications and used meta-analysis
to determine signiﬁcant overlaps (Supplementary Table
S10). The list of MDSR genes showed statistically
signiﬁcant overlaps with a variety of Myc-associated
expression proﬁles in either cultured cells or transgenic
mice, but very poor overlap with others, consistent with
the concept that Myc-regulated transcription is largely
context-dependent. The same is true for the list of genes
super-induced without Myc, which overlaps with
statistical signiﬁcance with some lists of Myc-repressed
genes but not with others.
Of particular relevance to the present study, the
response to serum in human ﬁbroblasts was functionally
related to a wound-healing response (Iyer et al., 1999), a
serum/wound-like proﬁle was enriched in a variety of
tumors (Chang et al., 2004) and overexpressed Myc and
CSN5 were identiﬁed as coordinate inducers of this
proﬁle (Adler et al., 2006). Of the 234 Myc-bound
MDSR genes identiﬁed here, 17 where also induced by
serum in human ﬁbroblasts in one study (Chang et al.,
2004) (Supplementary Table S10, list 14737219_1),
representing a moderate but statistically signiﬁcant
enrichment (of note, the signiﬁcance of this overlap
increased if we considered all our serum-induced genes,
that is, MDSR, MISR and super-induced without Myc).
However, only four of these genes were part of the Myc/
CSN5-induced wound-healing proﬁle (list 16518402_1),
pointing to signiﬁcant differences in the programs driven
by endogenous and overexpressed Myc in those settings.
Another serum-response proﬁle in human cells (Iyer
et al., 1999) showed no signiﬁcant overlap with our
MDSR group.
Myc was identiﬁed as a driver of a cancer-associated,
ESC-like signature in either human or mouse (Wong
et al., 2008): the mouse ESC-like module (Supplemen-
tary Table S10, list 18397753_1) as well as the human/
mouse module (list 18397753_4) were enriched among
our MDSR genes, in either the bound or unbound
subgroups. Thus, the ‘ESC-like’ module appears highly
related to the function of Myc during serum stimulation.
It has been shown, however, that this original ‘ESC-like’
module is unrelated to the program regulated by
pluripotency factors in ES cells, but rather corresponds
to a Myc program common to ES and cancer cells (Kim
et al., 2010). Indeed, our MDSR genes showed
signiﬁcant overlap with the Myc module, but not with
the core pluripotency model of the latter study
(Supplementary Table S10, lists 20946988_1 and 3).
Myc is also required for the maintenance of plur-
ipotency in ES cells (Cartwright et al., 2005) and when
co-expressed with the ES-speciﬁc factors Oct3/4, Sox2
and Klf4, can contribute to reprogram ﬁbroblasts to an
‘induced pluripotent state’ (iPS) analogous to that of ES
cells (Takahashi and Yamanaka, 2006). Myc binding in
our work (whether total or the MDSR subset) showed
very signiﬁcant overlaps with the Myc-binding proﬁles
in ES cells (lists 19030024_1, 18555785_1, 18358816_9,
19167336_3, 18555785_2 and 19079543_1), as well as in
ﬁbroblasts either fully or partially reprogrammed to the
induced pluripotent state (lists 19167336_7 and
19167336_11) (Sridharan et al., 2009). These overlaps
in binding proﬁles are summarized in Supplementary
Table S11. However, we also note that a set of genes
reported to be induced by Myc activation in mouse
embryonic ﬁbroblasts (Sridharan et al., 2009) showed
overlap neither with our MDSR genes (Supplementary
Table S10, list 19167336_20) nor with our own Myc
activation proﬁle in mouse embryonic ﬁbroblasts
(unpublished data), calling for a re-evaluation of this
issue in future work. In particular, it remains unclear
whether Myc contributes a true ‘reprogramming’ acti-
vity or, most likely, endows cells with a growth state
ideal for reprogramming by the other factors, which
constitutes the common denominator of its activities in
ES cells, iPS reprogramming and cancer cells.
Another interesting observation is the overlap of
MDSR genes with clusters of genes regulated by serum
in mouse embryonic ﬁbroblasts in different cell-cycle
phases (Ishida et al., 2001). Myc-bound MDSR genes
speciﬁcally overlapped with the ‘G1 growth’ group of
genes that were induced in G1 and remained constant
through the following phases, as well as with the ‘G1/S
growth’ and ‘G1/S cycle’ groups, which were both
induced at the G1/S transition and either remained
constant later, or declined and were re-induced at the
following G1/S transition (Supplementary Table S10,
lists 11416145_4, 11416145_5 and 11416145_6). The
‘G1/S growth’ and ‘G1/S cycle’ clusters, like the MDSR
group, were enriched for genes involved in transcription,
RNA metabolism and DNA replication. Instead, we did
not see a signiﬁcant overlap between MDSR genes and
the subset of E2F-regulated ‘G1/S cycle’ genes described
in the same work (list 11416145_8). Consistent with this
ﬁnding, several E2F-bound or regulated lists of genes
considered in our meta-analysis showed no signiﬁcant
overlap with our MDSR genes, and we observed no
enrichment of the E2F consensus-binding site at Myc-
bound promoters (data not shown). Thus, although
cooperativity on a restricted subset of target genes
remains fully plausible (Leung et al., 2008), our data do
not support a general cross-talk between Myc and E2F-
family proteins. Instead our group of genes super-
induced without Myc shows a signiﬁcant overlap with
the ‘Early G1 cluster’ and ‘G1 cycle cluster’ groups,
conﬁrming the relevance of negative gene regulation by
Myc during cell-cycle re-entry.
Functional screening of MDSR genes
Conditional deletion experiments show that c-myc is
required for cells to enter the cell cycle and reach S-
phase following mitogenic stimulation (Figure 1d)
(Trumpp et al., 2001). Therefore, MDSR genes—or a
subset of them—are likely to be important for G0-S-
phase progression. To address this question, near-
conﬂuent c-myc
f/f 3T9 cells (the same cells used above,
but without CreER) were infected with a recombinant
lentivirus or retrovirus expressing a speciﬁc small-
hairpin RNA (shRNA), after which the cells were
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for 48h (Figure 6a). In this manner, RNA interference
was induced while the cells were becoming quiescent
(through starvation and contact inhibition), circumvent-
ing prior antiproliferative defects. The cells were then re-
seeded in serum-containing medium and harvested after
16, 20, 24 and 28h: just before harvesting, the cells were
exposed to a 20-min pulse of 5-bromodeoxyuridine
(BrdU) incorporation for ﬂow-cytometric analysis of
DNA synthesis. In parallel, plates were seeded at lower
densities for colony formation assays. A pilot experi-
ment with an shRNA insert targeting c-myc (which
achieved 88% knockdown of the mRNA; data not
shown) showed reduced and delayed progression into
the S and G2/M phases relative to cells infected with a
control vector (Figure 6b).
In order to target individual MDSR genes, we used
shRNA-mir inserts, which mimic the structure of
natural primary microRNA transcripts (Silva et al.,
2005). A series of inserts targeting 29 of our MDSR
genes was initially obtained in the second-generation
lentiviral vector pGIPZ (Thermo Fisher Scientiﬁc,
Huntsville, AL, USA): however, this caused a subopti-
mal knockdown of all target mRNAs in 3T9 ﬁbroblasts.
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Figure 6 Some MDSR genes are required for entry/progression into S-phase following serum stimulation. (a) A schematic
representation of the experimental approach: cells infected with shRNA vectors for the genes indicated were starved for 2 days and
then stimulated with serum. (b, c) Two-dimensional ﬂuorescence-activated cell sorter proﬁles of cells stimulated for the indicated time
period are shown, along with the percent of BrdU-positive cells measured at each time point. (d) Percentages of apoptotic cells, as
assayed by cleaved caspase-3 staining and ﬂow cytometry, following knockdown of the indicated genes and 24h of serum stimulation.
(e) Cells were infected with the indicated shRNA retroviruses or with a non-silencing control shRNA. Puromycin-selected cells were
trypsinized and plated in duplicate for colony formation assay. After 10–12 days of culture, cells were ﬁxed and stained with crystal
violet. A representative experiment is shown.
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et al., 2005), the same shRNA-mir inserts effectively
knocked down their target mRNAs (Supplementary
Table S12). Knockdown of three MDSR genes, Mcm6,
Bxdc1 and Nutf2, caused defects in entry/progression
into S-phase following serum stimulation (Figure 6c).
Closer examination of ﬂuorescence-activated cell sorter
proﬁles showed that Mcm6 knockdown prevented
neither entry, nor early progression (until 20h), but
prevented the completion of DNA replication. Knock-
down of Bxdc1 also did not impair entry, but caused a
delay of B4h in S-phase progression, whereas that of
Nutf2 delayed both S-phase entry and progression,
suggesting a defect in the G0–G1 and/or G1–S transi-
tions. Cleaved caspase-3 staining proﬁles determined
28h following serum stimulation revealed enhanced
apoptosis in Nutf2-targeted cells, but not in the others
(Figure 6d). Knockdown of the three genes also heavily
impaired colony outgrowth (Figure 6e). The above data
were reproduced with two independent shRNA-mir
hairpins for either Mcm6 or Bxdc1 (data not shown). Of
three additional Myc-target genes tested, Cad also
showed a requirement for S-phase entry but Odc1 and
Cul1 did not (Supplementary Table S11), contrasting
previous conclusions on Cul1 (O’Hagan et al., 2000).
Finally, targeting 11 MDSR genes (Serbp1, Cct7, Prmt3,
Sfrs7, Mybbp1a, Hspd1, Gart, Thop1, Gpatch4, Mcm5
and Exosc2) caused no delay in the ﬁrst S-phase, but
impaired colony formation (data not shown; Supple-
mentary Table S11), implying a defect in proliferation
and/or survival at later stages, whereas 15 other MDSR
genes showed no obvious requirement in our experi-
ments.
Discussion
We have combined mRNA proﬁling and genome-wide
mapping of Myc–DNA interactions to identify MDSR
genes in mouse ﬁbroblasts. For a gene to be included in
the MDSR group, its mRNA had to be induced by at
least 1.5-fold either 4 or 8h following serum stimulation,
and its response had to be reduced by 1.5-fold or more
in the absence of Myc, as determined in our microarray
data set (see Materials and methods). Validation by
quantitative RT–PCR showed that MDSR genes were
identiﬁed with high conﬁdence by these criteria. Con-
ceivably, subtler regulation of a larger number of genes
may also be a relevant aspect of Myc’s activity, but is
below the threshold of conﬁdence for microarray
analysis. As such, our list of 298 MDSR genes can be
considered as the core mRNA program controlled by
Myc upon mitogenic stimulation in mouse ﬁbroblasts.
Consistent with the fact that Myc can also repress
transcription (Adhikary and Eilers, 2005), we conﬁrmed
the existence of genes that are either repressed in a Myc-
dependent manner, or super-induced in the absence of
Myc. As the rates of RT–PCR validation for these gene
groups in our data set were lower than for the Myc-
activated MDSR genes, we concentrated here on the
latter. Another aspect that remains to be addressed in
the context of mitogenic stimulation is the role of Myc
in regulating microRNAs, a phenomenon that is central
to Myc’s transforming activity (Klapproth and Wirth,
2010).
Our ChIP-seq analysis revealed that about half of all
Myc-binding sites in the genome clustered in the interval
between  1000 and þ1000bp from a TSS. As many as
78.5% (234/298) of the MDSR promoters—against
22.4% (4284/19157) of all the promoters identiﬁed in
our data set—were bound by Myc within this interval,
implying that most MDSR genes were directly regulated
by Myc. Those genes represented a minor part (234/4284
or 5.5%) of all the genes targeted by Myc in the genome,
but on average were bound with much higher efﬁciency,
raising the possibility that Myc-binding levels deter-
mined Myc-dependent regulation. This was ruled out,
however, as we were able to identify 718 non-MDSR
genes that were bound by Myc at 650 different sites as
efﬁciently—if not better—as most MDSR genes. Thus,
efﬁcient DNA binding by Myc did not automatically
lead to Myc-dependent transcriptional activation.
All of the promoters with high afﬁnity for Myc
(whether MDSR or not) showed frequent occurrences of
CpG islands and E-boxes, indicating that those sequence
elements determine promoter recognition, as expected
(Fernandez et al., 2003; Zeller et al., 2006), but not gene
regulation per se. Our data are also consistent with the
concept that promoter recognition by Myc initially
occurs through non-sequence speciﬁc interactions with
active chromatin domains (Guccione et al., 2006),
followed in a second step by direct DNA binding.
Relative to promoters with no trace of Myc binding
(that is, no peak at all in ChIP-seq), those with low levels
of Myc interaction (OCR-RMA p15) already showed
signiﬁcant enrichment for CpG islands, most likely
reﬂecting the permissive chromatin conﬁguration gen-
erally present at those domains. The E-box, on the other
hand, was most signiﬁcantly enriched in the promoters
with the highest Myc levels, reﬂecting the sequence-
speciﬁc interaction of Myc with those sites.
Our ChIP-seq data also indicated that several variants
of the core E-box and ﬂanking nucleotides are tolerated
in vivo (Table 2), largely conﬁrming predictions made
based on DNA binding in vitro or in yeast (Blackwell
et al., 1993; Grandori et al., 1996). Remarkably, the core
hexamer inﬂuenced the preferred ﬂanking nucleotides
(analyzed here independently for positions ±1, ±2a n d
±3). In the presence of a canonical CACGTG element
(core #1), T and A were strongly counter-selected at the
 1 and þ1 positions, respectively (Fisher et al., 1993;
Solomon et al., 1993) but other bases were all tolerated,
and positions ±2 and ±3 had no signiﬁcant inﬂuence
on Myc binding. In the presence of variant cores, the
consensus at all ﬂanking positions was more restrictive,
with fewer variants being allowed. In two instances
(position ±2 with core #2 and position ±3w i t hc o r e
#5) distinct combinations were preferred, the base on
one side inﬂuencing that on the other (Table 2). It is
noteworthy that the sub-optimal variant TCACGTGA
is the preferred consensus for TFE3, a bHLH-LZ factor
that regulates lysosomal genes (Sardiello et al., 2009),
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determining the selectivity of bHLH-family proteins
that bind to the same E-box toward distinct groups of
genes.
Our data directly illustrate the fact that Myc binds to
a large number of genes, but is critical for the regulation
of only a subset of those genes in any given physiological
context. We speculate that differences in environment,
signaling events and/or cell type will determine the
regulation of alternative subsets of target genes, possibly
with relatively unchanged DNA-binding proﬁles. An
example is provided by Snai1, a gene activated by
transforming growth factor-b in a Myc-dependent
manner in mammary epithelial cells: Snai1 was bound
by Myc also in ﬁbroblasts, but showed a Myc-
independent serum response (MISR; Supplementary
Table S4 and Supplementary Figure S3) (Smith et al.,
2009). Five genes that were co-regulated by Myc and the
estrogen receptor in human mammary epithelial cells
(GABPB2, HK2, RCC2, SAMHD1 and SYVN1) (Cheng
et al., 2006) were also bound by Myc in mouse
ﬁbroblasts, but were not found in the MDSR group.
In addition, target genes showing no Myc-dependent
regulation in a given physiological setting may respond
to the oncogenic activation of Myc in the same cell type:
for example, more than 200 of the Myc-bound non-
MDSR genes identiﬁed here were induced upon ectopic
Myc activation in mouse embryonic ﬁbroblasts (unpub-
lished data).
The MDSR group was enriched for genes involved in
metabolic and biosynthetic processes, with particular
representation of genes favoring ribosome biogenesis,
protein biosynthesis, nucleotide biosynthesis and DNA
replication (see section Results), consistent with pre-
vious lists of Myc-regulated genes and with the critical
roles of Myc in these processes (Schlosser et al., 2003;
Barna et al., 2008; Liu et al., 2008; Dang et al., 2009;
Herold et al., 2009; van Riggelen et al., 2010), and in
particular in the regulation of cell growth (Mateyak
et al., 1997; Iritani and Eisenman, 1999; Schuhmacher
et al., 1999).
In order to address the function of MDSR genes, we
knocked down 29 individual mRNAs in quiescent cells:
three of these MDSR gene products were required for
normal S-phase entry or progression following serum
stimulation, 11 were needed to sustain colony forma-
tion, whereas 15 others showed no obvious requirement
in our experiments (Supplementary Table S12). Of
particular interest, several subunits of the Mcm complex
were included in our MDSR list: of these, we targeted
Mcm5 and Mcm6 by RNA interference. Neither of these
proteins was required for S-phase entry and early
progression following serum stimulation. This is in line
with the notion that the Mcm complex (Mcm2–7),
which is required for origin licensing, is pre-loaded on
replication origins in the precedent mitosis (Blow and
Dutta, 2005; Blow and Tanaka, 2005). Therefore, after
G0 exit, Mcm proteins do not need to be synthesized
de novo for origin ﬁring in the ﬁrst S-phase. The Mcm
complex is also required for the progression of replica-
tion forks (Blow and Dutta, 2005; Blow and Tanaka,
2005). In our hands, Mcm6 but not Mcm5 knockdown
prevented the completion of S-phase, suggesting that
Mcm6 may turn over more rapidly, and that its
synthesis becomes limiting already during the ﬁrst cell
cycle. As expected, both Mcm5 and Mcm6 were
essential for subsequent proliferation, as judged by the
colony formation assays.
The two other MDSR genes showing a requirement in
the ﬁrst S-phase were Bxdc1 and Nutf2. The Bxdc1
product is a Brix-domain protein that localizes to the
nucleolus in an RNA-dependent manner and partici-
pates in rRNA maturation (Hirano et al., 2009). Nutf2,
on the other hand, mediates the nuclear import of the
Ran GTPase (Ribbeck et al., 1998; Smith et al., 1998), a
key regulator of nucleocytoplasmic trafﬁcking (Stewart,
2007). Nutf2 is essential for viability both in Caenor-
habditis elegans and Saccharomyces cerevisiae, and in the
latter its interaction with Ran is required for cell-cycle
progression (Corbett and Silver, 1996; Quimby et al.,
2000a,b).
In summary, we have identiﬁed a group of 298 MDSR
genes, which constitutes the core mRNA expression
program driven by Myc in this physiological setting.
This group is highly consistent with the role of Myc in
cell-cycle entry, cell growth, protein biosynthesis and
DNA replication. We surmise that concerted upregula-
tion of these genes is critical for the optimal response of
cells to mitogenic stimuli, as well as for sustained cell
growth and proliferation. The binding of Myc to a much
larger number of loci, and the concept that different
subsets of target genes are regulated by Myc under
different physiological conditions, permit rationalizing
the involvement of this transcription factor in diverse
signaling pathways and biological responses. This
complexity may also underlie the involvement of Myc
as a driving oncogene in a variety of neoplasias.
Materials and methods
Details on Materials and methods are provided in full detail in
the Supplementary information.
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